Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for ...
Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...
The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. The decision expands DARZALEX FASPRO’s ...
Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results